Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RUBY trial of dostarlimab plus carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer
2019-001576-11Phase 3Active
- Sponsor
- TESARO, Inc.
- Start
- Jul 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in endometrial cancer (EC) comparing Dostarlimab plus carboplatin-paclitaxel with Placebo plus carboplatin-paclitaxel (2 arms). Primary endpoint: Progression-free survival. Started Jul 2019; status: active.
02
Drugs
dostarlimab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on 2019-001576-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001576-11.